title: Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
abstract: Nine hundred and ten schizophrenic inpatients suffering from acute psychotic episodes were included in a naturalistic study. Patients were prescribed treatment with olanzapine (OLZ) or with typical antipsychotic (TYP) drugs. Patients receiving another atypical antipsychotic were excluded. Of the whole sample, 483 (53.4%) were treated with olanzapine and 421 (46.6%) with typical antipsychotics. Three specific subpopulations of greater severity were defined: patients with prominent psychotic symptoms, agitated patients, and patients initially treated with intramuscular (i.m.) medication because of their acute clinical condition. Severity of illness was assessed using the Clinical Global Impression (CGI) scale for severity, the Brief Psychiatric Rating Scale (BPRS) and the Nursing Observational Scale for Inpatient Evaluation. Baseline differences were adjusted per data analysis. The mean change from baseline to endpoint of overall symptomatology (total BPRS score) was significantly greater in the olanzapine group compared to the typical antipsychotic-treated group, both in the sample of patients with prominent positive symptoms (P < 0.001) and in the sample of agitated patients (P =0.015). Significant differences were also found in BPRS positive scores, BPRS negative scores and CGI scores in these two populations. Patients who had received previous i.m. drugs showed no statistically significant differences in symptomatic improvement between both treatments groups, except for a more favourable response of BPRS negative subscores in the olanzapine group (P =0.015). The results suggest that olanzapine may be considered as a first line treatment for severely psychotic inpatients with schizophrenia.
authors.affiliation: Fundación Jiménez Díaz, Madrid, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Carrasco
authors.forename: M
authors.initials: M
authors.lastname: Gutiérrez
authors.forename: J C
authors.initials: JC
authors.lastname: Gómez
authors.forename: R
authors.initials: R
authors.lastname: Escobar
authors.forename: E
authors.initials: E
authors.lastname: Alvarez
authors.forename: F
authors.initials: F
authors.lastname: Cañas
authors.forename: J
authors.initials: J
authors.lastname: Bobes
authors.forename: J
authors.initials: J
authors.lastname: Gascón
authors.forename: J
authors.initials: J
authors.lastname: Gibert
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001569:Benzodiazepines; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine